Investigational drugs in Phase II clinical trials for the treatment of obesity: Implications for future development of novel therapies

Expert Opinion on Investigational Drugs

Volumn 23, Issue 8, 2014, Pages 1055-1066

  Jackson, V Margaret ^a   Price, David A ^a   Carpino, Philip A ^a  

^a PFIZER INC   (United States)

Author keywords

Beloranib; Bupropion zonisamide; GSK 2890457; HPP404; Investigational drugs; KD026; Obesity; Patient stratification; Phase II; Remogliflozin etabonate; RM 493

Indexed keywords

AMFEBUTAMONE PLUS ZONISAMIDE; ANTIOBESITY AGENT; GSK 2890457; HPP 404; KD 026; REMOGLIFLOZIN ETABONATE; RM 493; UNCLASSIFIED DRUG; NEW DRUG;

BODY WEIGHT; GENOTYPE; HOMEOSTASIS AND REGULATION; HUMAN; OBESITY; REVIEW; STRATIFICATION; TREATMENT OUTCOME; WEIGHT REDUCTION; ANIMAL; DRUG DESIGN; DRUG EFFECTS; OBESITY, MORBID; PHASE 2 CLINICAL TRIAL (TOPIC);

ANIMALS; ANTI-OBESITY AGENTS; CLINICAL TRIALS, PHASE II AS TOPIC; DRUG DESIGN; DRUGS, INVESTIGATIONAL; HUMANS; OBESITY; OBESITY, MORBID; WEIGHT LOSS;

EID: 84904313098     PISSN: 13543784     EISSN: 17447658     Source Type: Journal    
DOI: 10.1517/13543784.2014.918952     Document Type: Review

References (78)

1. Hetherington MM, Cecil JE. Gene-environment interactions in obesity. Forum Nutr 2010;63: 195-203
2. Compared with whites, Blacks had 51% higher and Hispanics had 21% higher obesity rate. Centers for Disease Control, Atlanta, GA, 2014. Available from: Http: //www.cdc.gov/Features/ dsObesityAdults/
3. Gale SM, Castracane VD, Mantzoros CS. Energy homeostasis, obesity and eating disorders: Recent advances in endocrinology. J Nutr 2004;134: 295-8
4. Finkelstein EA, Trogdon JG, Cohen JW, et al. Annual medical spending attributable to obesity: Payer-And servicespecific estimates. Health Aff 2009;28: W822-31
5. Schneider BE, Mun EC. Surgical management of morbid obesity. Diabetes Care 2005;28: 475-80
6. Suter M, Calmes JM, Paroz A, et al. Results of Roux-en-Y gastric bypass in morbidly obese vs superobese patients: Similar body weight loss, correction of comorbidities, and improvement of quality of life. Arch Surg 2009;144: 312-18.discussion 18
7. Heal DJ, Gosden J, Smith SL. A review of late-stage CNS drug candidates for the treatment of obesity. Int J Obes 2013;37: 107-17
8. Valentino MA, Lin JE, Waldman SA. Central and peripheral molecular targets for antiobesity pharmacotherapy. Clin Pharmacol Ther 2010;87: 652-62
9. Ioannides-Demos LL, Proietto J, Tonkin AM, et al. Safety of drug therapies used for weight loss and treatment of obesity. Drug Saf 2006;29: 277-302
10. Yanovski SZ, Yanovski JA. Long-Term drug treatment for obesity: A systematic and clinical review. J Am Med Assoc 2014;311: 74-86
11. Jain SS, Ramanand SJ, Ramanand JB, et al. Evaluation of efficacy and safety of orlistat in obese patients. Indian J Endocrinol Metab 2011;15: 99-104
12. Woloshin S, Schwartz LM. The new weight-loss drugs, lorcaserin and phentermine-Topiramate: Slim pickingš JAMA Intern Med 2014;174: 615-19
13. Aronne LJ, Wadden TA, Peterson C, et al. Evaluation of phentermine and topiramate versus phentermine/ topiramate extended-release in obese adults. Obesity (Silver Spring) 2013;21: 2163-71
14. Shin JH, Gadde KM. Clinical utility of phentermine/topiramate (Qsymia) combination for the treatment of obesity. Diabetes Metab Syndr Obes 2013;6: 131-9
15. Astrup A, Rossner S, Van Gaal L, et al. Effects of liraglutide in the treatment of obesity: A randomised, double-blind, placebo-controlled study. Lancet 2009;374: 1606-16
16. Apovian CM, Aronne L, Rubino D, et al. A randomized, phase 3 trial of naltrexone SR/bupropion SR on weight and obesity-related risk factors (COR-II). Obesity (Silver Spring) 2013;21: 935-43
17. Kopelman P, Groot Gde H, Rissanen A, et al. Weight loss, HbA1c reduction, and tolerability of cetilistat in a randomized, placebo-controlled phase 2 trial in obese diabetics: Comparison with orlistat (Xenical). Obesity (Silver Spring) 2010;18: 108-15
18. Novo Nordisk reports 8% weight loss in phase 3a obesity trial with liraglutide 3 mg. Novo Nordisk, 2013. Available from: Http: //www. novonordisk.com/include/asp/ exe-news-Attachment.asp? sAttachmentGUID=3f254ec7- 1b91-4334-bf0d-572d4e6a4c3e
19. Witkamp RF. Current and future drug targets in weight management. Pharm Res 2011;28: 1792-818
20. Erondu N, Wadden T, Gantz I, et al. Effect of NPY5R antagonist MK-0557 on weight regain after very-low-calorie diet-induced weight loss. Obesity (Silver Spring) 2007;15: 895-905
21. Nathan PJ, O'Neill BV, Napolitano A, et al. Neuropsychiatric adverse effects of centrally acting antiobesity drugs. CNS Neurosci Ther 2011;17: 490-505
22. Dietrich MO, Horvath TL. Limitations in anti-obesity drug development: The critical role of hunger-promoting neurons. Nat Rev Drug Discov 2012;11: 675-91
23. King BM. The rise, fall, and resurrection of the ventromedial hypothalamus in the regulation of feeding behavior and body weight. Physiol Behav 2006;87: 221-44
24. Collins S, Cao W, Daniel KW, et al. Adrenoceptors, uncoupling proteins, and energy expenditure. Exp Biol Med 2001;226: 982-90
25. Antel J, Gregory PC, Nordheim U. CB1 cannabinoid receptor antagonists for treatment of obesity and prevention of comorbid metabolic disorders. J Med Chem 2006;49: 4008-16
26. Cota D, Tschop MH, Horvath TL, et al. Cannabinoids, opioids and eating behavior: The molecular face of hedonism? Brain Res Rev 2006;51: 85-107
27. Volkow ND, Wang G-J, Baler RD. Reward, dopamine and the control of food intake: Implications for obesity. Trends Cogn Sci 2011;15: 37-46
28. Roses AD. Stimulation of cholecystokinin-A receptors With Gl181771X: A failed clinical trial that did not test the pharmacogenetic hypothesis for reduction of food intake. Clin Pharmacol Ther 2009;85: 362-5
29. Santoro N, del Giudice EM, Grandone A, et al. Y2 receptor gene variants reduce the risk of hypertension in obese children and adolescents. J Hypertens 2008;26: 1590-4
30. Heymsfield SB, Greenberg AS, Fujioka K, et al. Recombinant leptin for weight loss in obese and lean adults, A randomized, controlled, dose-escalation trial. JAMA 1999;282: 1568-75
31. Ravussin E, Smith SR, Mitchell JA, et al. Enhanced weight loss with pramlintide/ metreleptin: An integrated neurohormonal approach to obesity pharmacotherapy. Obesity (Silver Spring) 2009;17: 1736-43
32. Tam CS, Lecoultre V, Ravussin E. Novel strategy for the use of leptin for obesity therapy. Expert Opin Biol Ther 2011;11: 1677-85
33. Ahima RS, Prabakaran D, Mantzoros C, et al. Role of leptin in the neuroendocrine response to fasting. Nature 1996;382: 250-2
34. Rosenbaum M, Murphy EM, Heymsfield SB, et al. Low dose leptin administration reverses effects of sustained weight-reduction on energy expenditure and circulating concentrations of thyroid hormones. J Clin Endocrinol Metab 2002;87: 2391-4
35. Kim EJ, Shin WH. General pharmacology of CKD-732, a new anticancer agent: Effects on central nervous, cardiovascular, and respiratory system. Biol Pharm Bull 2005;28: 217-23
36. Kim YM, An JJ, Jin Y-J, et al. Assessment of the anti-obesity effects of the TNP-470 analog, CKD-732. J Mol Endocrinol 2007;38: 455-65
37. Zafgen, Inc., USA. Treating hypothalamic obesity with methionine aminopeptidase 2 (MetAP2) inhibitors. WO2013169857A1; 2013
38. Chun E, Han CK, Yoon JH, et al. Novel inhibitors targeted to methionine aminopeptidase 2 (MetAP2) strongly inhibit the growth of cancers in xenografted nude model. Int J Cancer 2005;114: 124-30
39. Zafgen announces cardiovascular data from phase 1b study of ZGN-433 in obesity at American diabetes association annual meeting. Zafgen, Cambridge, MA; 2011. Available from: Http: //zafgen.com/ zafgen/newsroom/news-detailš ID=f678c3b2-5885-6f14-8089-ff0000fc4595
40. Hughes TE, Kim DD, Marjason J, et al. Ascending dose-controlled trial of beloranib, a novel obesity treatment for safety, tolerability, and weight loss in obese women. Obesity (Silver Spring) 2013;21: 1782-8
41. Rossi J, Balthasar N, Olson D, et al. Melanocortin-4 receptors expressed by cholinergic neurons regulate energy balance and glucose homeostasis. Cell Metab 2011;13: 195-204
42. Greenfield JR, Miller JW, Keogh JM, et al. Modulation of blood pressure by central melanocortinergic pathways. N Engl J Med 2009;360: 44-52
43. Krishna R, Gumbiner B, Stevens C, et al. Potent and selective agonism of the melanocortin receptor 4 with MK-0493 does not induce weight loss in obese human subjects: Energy intake predicts lack of weight loss efficacy. Clin Pharmacol Ther 2009;86: 659-66
44. A two part trial investigating an antiobesity drug in overweight/obese male and female healthy volunteers. National Institutes of Health, Washington, DC; 2014. Available from: Http: //clinicaltrials. gov/ct2/show/NCT01044108? term=NNC+0070-0002-0453&rank=1
45. Sohn J-W, Harris LE, Berglund ED, et al. Melanocortin 4 receptors reciprocally regulate sympathetic and parasympathetic preganglionic neurons. Cell 2013;152: 612-19
46. Kievit P, Halem H, Marks DL, et al. Chronic treatment with a melanocortin-4 receptor agonist causes weight loss, reduces insulin resistance, and improves cardiovascular function in diet-induced obese rhesus macaques. Diabetes 2013;62: 490-7
47. Phase 2 study to evaluate safety and efficacy of Rm-493 in obese patients. National Institutes of Health, Washington, DC; 2014. Available from: Http: //clinicaltrials. gov/ct2/show/NCT01749137?term=RM-493&rank=1
48. Effects of RM-493 on energy expenditure in obese individuals. National Institutes of Health, Washington, DC; 2014. Available from: Http: //clinicaltrials. gov/ct2/show/NCT01867437?term=RM-493&rank=2
49. Rhythm Pharmaceuticals, Inc., USA. Method of treating melanocortin-4 receptor-Associated disorders in heterozygous carriers comprising melanocortin-4 receptor agonist peptides. WO2013102047A1; 2013
50. Ipsen grants Rhythm exclusive worldwide license for two programs in the field of metabolic disorders. Boston, MA; 2010. Available from: Http: //www. rhythmtx.com/NEWS/releases/031210. html
51. Ipsen Pharma. A sustained-release composition containing peptides as active ingredient. WO2012172433A2; 2012
52. Societe de Conseils de Recherches et D'Applications Scientifiques S.A.S., Fr.; Louisiana State University and Agriculture and Mechanical College; Ipsen Pharma. Use of melanocortin receptor agonist peptide compounds to treat insulin resistance. WO2009061411A2; 2009
53. A safety and efficacy study of HPP404 on weight loss in overweight or obese subjects. National Institutes of Health, Washington, DC; 2014. Available from: Http: //clinicaltrials. gov/ct2/show/NCT01540864? term=HPP404&rank=1
54. Passani MB, Blandina P, Torrealba F. The histamine H3 receptor and eating behavior. J Pharmacol Exp Ther 2011;336: 24-9
55. Berlin M, Boyce CW, de Lera Ruiz M. Histamine H3 receptor as a drug discovery target. J Med Chem 2011;54: 26-53
56. de Lera Ruiz M, Zheng J, Berlin MY, et al. Bicyclic and tricyclic heterocycle derivatives as histamine H3 receptor antagonists for the treatment of obesity. Bioorg Med Chem Lett 2013;23: 6004-9
57. Novo Nordisk A/S, Den. Preparation of 3-(1, 3-benzodioxol-5-yl)-6-(4- cyclopropylpiperazin-1-yl)pyridazine as a histamine H3 receptor antagonist. WO2007137968A1; 2007
58. Kim E, Campbell S, Schueller O, et al. A small-molecule inhibitor of enterocytic microsomal triglyceride transfer protein, SLx-4090: Biochemical, pharmacodynamic, pharmacokinetic, and safety profile. J Pharmacol Exp Ther 2011;337: 775-85
59. Phase 2 study of orlistat and SLx-4090 for the treatment of type 1 hyperlipoproteinemia. National Institutes of Health, Washington, DC; 2014. Available from: Http: //clinicaltrials. gov/ct2/show/NCT01675154?term=SLx- &rank=1
60. Clinical pipeline. Kadmon, 2014. Available from: Http: //kadmon. com/docs/science-pipeline
61. Cuchel M, Rader DJ. Microsomal transfer protein inhibition in humans. Curr Opin Lipidol 2013;24: 246-50
62. Wren JA, King VL, Campbell SL, et al. Biologic activity of dirlotapide, a novel microsomal triglyceride transfer protein inhibitor, for weight loss in obese dogs. J Vet Pharmacol Ther 2007;30: 33-42
63. Hata T, Mera Y, Kawai T, et al. JTT-130, a novel intestine-specific inhibitor of microsomal triglyceride transfer protein, ameliorates impaired glucose and lipid metabolism in Zucker diabetic fatty rats. Diabetes Obes Metab 2011;13: 629-38
64. Fujimori Y, Katsuno K, Nakashima I, et al. Remogliflozin etabonate, in a novel category of selective low-Affinity sodium glucose cotransporter (SGLT2) inhibitors, exhibits antidiabetic efficacy in rodent models. J Pharmacol Exp Ther 2008;327: 268-76
65. Kapur A, O'Connor-Semmes R, Hussey EK, et al. First human doseescalation study with remogliflozin etabonate, a selective inhibitor of the sodium-glucose transporter 2 (SGLT2), in healthy subjects and in subjects with type 2 diabetes mellitus. BMC Pharmacol Toxicol 2013;14: 26
66. BHV Pharma-Our pipeline. BHV Pharma, 2014. Available from: Http: //www.bhvpharma.com/pipeline/
67. Bays HE, Weinstein R, Law G, et al. Canagliflozin: Effects in overweight and obese subjects without diabetes mellitus. Obesity (Silver Spring) 2014;22: 1042-9
68. Cefalu WT. Paradoxical insights into whole body metabolic adaptations following SGLT2 inhibition. J Clin Invest 2014;124: 485-7
69. To investigate the safety, tolerability and pharmacodynamics of GSK2890457 in healthy volunteers and subjects with type 2 diabetes. National Institutes of Health, Washington, DC; 2014. Available from: Http: //clinicaltrials. gov/ct2/show/NCT01725126?term=GSK-2890457&rank=1
70. Ornellas T, Chavez B. Naltrexone SR/ bupropion SR (Contrave): A new approach to weight loss in obese adults. P T 2011;36: 255-62
71. Empatic. Orexigen; 2014. Available from: Http: //www. orexigen.com/product-candidates/ empatic.html
72. Exenatide in extreme pediatric obesity. National Institutes of Health, Washington, DC; 2014. Available from: Http: //clinicaltrials. gov/ct2/show/NCT01237197? term=exenatide+and+Minnesota&rank=2
73. Topiramate in adolescents with severe obesity. National Institutes of Health, Washington, DC; 2014. Available from: Http: //clinicaltrials. gov/ct2/show/NCT01859013? term=topiramate+and+minnesota&rank=1
74. The therapeutic effects of topiramate and metformin on second generation antipsychotics-induced obesity. National Institutes of Health, Washington, DC; 2014. Available from: Http: //clinicaltrials. gov/ct2/show/NCT01384279? term=topiramate+and+metformin+and+taiwan&rank=1
75. American Diabetes Association; American Psychiatric Association; American Association of Clinical Endocrinologists. et al. Consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care 2004;27: 596-601
76. Hypothalamic obesity following craniopharyngioma surgery: A pilot trial of combined metformin and diazoxide therapy. National Institutes of Health, Washington, DC; 2014. Available from: Http: //clinicaltrials. gov/ct2/show/NCT00892073? term=Craniopharyngioma++toronto&rank=1
77. Amlexanox for type 2 diabetes and obesity. National Institutes of Health, Washington, DC; 2014. Available from: Http: //clinicaltrials. gov/ct2/show/NCT01842282? term=amlexanox&rank=2
78. Reilly SM, Chiang SH, Decker SJ, et al. An inhibitor of the protein kinases TBK1 and IKK-varepsilon improves obesity-related metabolic dysfunctions in mice. Nat Med 2013;19: 313-21.